29. To Compare The Efficacy Of Continuous Low-Dose Infusion Of Dexmedetomidine & Intermittent Boluses of Dexmedtomidine In Preventing ICU Induced Delirium
Sadia Imran1, Usman ul Haq3, Imran ul Haq4, Muhammad Ali5, Muhammad Fareed Azam4 and Mahjabeen2
ABSTRACT
Objective: To compare the efficacy of continuous low-dose infusion of dexmedetomidine and intermittent boluses of dexmedetomidine in preventing ICU-induced delirium.
Study Design: Randomized controlled trial study.
Place and Duration of Study: This study was conducted at the Department of Critical Care Medicine, PIMS, Islamabad from 1st of September 2022 to 30th of November 2022.
Materials and Methods: 64 patients having RASS score >+2 or <-2, ICDSC score of 4 or greater, and Pre DELERIC score greater than 40% were enrolled through consecutive non-probability sampling. Patients were randomly allocated either to Group A for continuous infusion or Group B for intermittent boluses of dexmedetomidine. Delirium will be screened by the Pre DELERIC tool within 24 hours of admission and the delirium established in patients will be monitored by ICDSC score daily till there's no clinical evidence of delirium. The primary outcome was the efficacy of preventing ICU-induced delirium between the two groups in achieving an ICDSC score of ≤3.
Results: Age ranges from 22 to 75 years with a mean age of 39.81±13.48 years. The male gender was dominant with 42 (65.62%) patients. The treatment outcomes show no significant difference between the two groups regarding the Mean±SD of RASS and ICDSC score. There was no statistically significant difference in the number of patients achieving ICDSC scores of ≤3 between the two groups.
Conclusion: Continuous infusion of dexmedetomidine or its intermittent boluses are equally effective in the treatment of ICU-induced delirium.
Key Words: Critical care unit, Delirium, Dexmedetomidine.